Artialis has highlighted recent research which evaluated the impact of its Nasafytol supplement in hospitalised COVID-19 patients.
Turmeric, quercetin and vitamin D are already known to have antiviral, antibacterial and immunomodulatory properties, the company says, but researchers wanted to know what positive effects the combination of these three substances could have on the virulence of COVID-19 and the development of the associated pneumonia.
For this study, 49 patients were enrolled and randomly separated into two groups. All patients were 18 or above and hospitalised with a severe form of the disease. In the first group, 25 patients received Nasafytol for up to 14 days in addition to standard treatment. In the second, 24 patients on standard treatment received vitamin D (equivalent dose of 800 IU) for up to 14 days. The only demographic difference between the groups was in their vaccination status, the company says, with a higher number of vaccinated patients (at least one dose) in the vitamin D group than in the supplementation group.
“For this study, we chose a combination of bioactive quercetin, a bioactive turmeric extract and vitamin D3, they help maintain the body's immune system and the effectiveness of the natural defences,” says Prof Yves Henrotin, founder and Executive Chair of Artialis and Professor at the Faculty of Medicine of the University of Liège.
“By combining these three elements, we wanted to develop a natural preparation that would help patients with COVID-19. On the one hand, by reducing the risk of serious complications, and on the other hand, by reducing the number of transfers and avoiding overcrowding in ICUs as much as possible. These were the main factors we had to take into account during the pandemic. That is why we tested this combination (Nasafytol®), as an addition to the standard treatment and in line with the WHO recommendations for clinical studies in relation to COVID-19.”
The group who received supplementation to standard treatment showed significant progress for all evaluated parameters. The group showed a significant reduction in the number of hospitalised patients: 59% on day 7 and 73% on day 14 compared to the vitamin D group.
Secondly, among the patients who received Nasafytol there was a significant increase, at 82%, in the number of patients discharged from hospital on day 7. In fact, 76% of them left the hospital on day 7, compared to only 42% of the patients in the vitamin D group.
Moreover, the reduction in the WHO clinical severity score for COVID-19 was significantly greater in the treatment group than in the vitamin group on day 7.
Dr Gérain, Head of Internal Medicine at Delta (CHIREC hospital group). “We are delighted with these results, and with the fact that we can offer a supplement to standard care, which will not only shorten the duration of hospital admissions and save lives, but also significantly reduce the workload of hospital staff.”
